It has been shown that a virosomal hepatitis A vaccine could improve immunogenicity in HIV-positive Thai children but no data are available for patients receiving immunosuppressive drugs.9,10
Odile Launay, MD
Universite Paris Descartes, Sorbonne Paris Cit ´ e, H´ opital Cochin, CIC de Vaccinologie Cochin Pasteur, Paris, France
Furthermore, the IVE was calculated on the basis of ORs determined using a random effects model, which allowed us to take into account potential differences, including type of vaccine, vaccination programs, the levels of immunity across different population and settings, and different use of hospital emergency departments [36], [37].
37.Puig-Barbera J, Natividad-Sancho A, Calabuig-Perez J, Lluch-Rodrigo JA, Pastor-Villalba E, et al. (2013) MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine 31: 3995–4002.
Vaccination against viral hepatitis of HIV-1 infected patients
the immunogenicity of a virosome-formulated HAV vaccine (Epaxal®, Berna Biotech Ltd.) has been evaluated, in 14 HIV-positive adults and 64 healthy adults, who received a primary immunisation (1 dose at day 1) and a booster dose 12 mo later.28